Mashup Score:43
cibmtr.orgCIBMTR Working Committee Training and Leadership (CTL) Program - 2 weeks
Mashup Score:43
Mashup Score:43
cibmtr.orgCIBMTR Working Committee Training and Leadership (CTL) Program - 2 weeks
Mashup Score:43
Mashup Score:29
American Society of HematologyUsing 3 illustrative cases, Chaer et al discuss the options for the prevention and therapy of COVID-19 infection in patients with hematologic malignancies and...
How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies [Aug 18, 2022] @FirasElChaer , Auletta, @ChemalyRoy @BloodJournal https://t.co/JIfU1A6USH #bmtsm #CARTcell #leusm #lymsm #mmsm #mpnsm https://t.co/JIfU1A6USH - view on twitter
Mashup Score:25
American Society of HematologyKey Points. The development of second primary malignancy post-auto-HSCT for myeloma is associated with inferior progression-free and overall survival.Multiple...
Impact of SPM Post-AutoSCT on MM. Incidence: 4%. SPM associated with worse PFS, but MM remains the primary cause of death in SPM patients @CIBMTR @szusmani @BKRagonMD @adsouza_md #mmsm #bmtsm https://t.co/NOX1N9cBlA - view on twitter
Mashup Score:22
American Society of HematologyKey Points. The development of second primary malignancy post-auto-HSCT for myeloma is associated with inferior progression-free and overall survival.Multiple...
Important @CIBMTR #myeloma study by Dr Ragon @szusmani et al: 4% #auto BMT recipients developed 2nd cancer at median ~3yr follow up; 2nd cancers associated w/⬇️PFS & OS; myeloma still main cause of death #mmsm #bmtsm https://t.co/CDrd86AkEL - view on twitter
Mashup Score:19
ScienceDirectRecent ASTCT guidelines have sought to establish clinical and research expectations for participants in blood and marrow transplantation (BMT) and...
Demographics, motivations, and experiences of participants in transplantation or cellular therapy fellowships @RahulBanerjeeMD @BldCancerDoc @amarkelkar @TheodoraAnagno1 @hemedoc @mikinishitanimd @ASTCT_Journal @ASTCT #bmtsm #TcellRx #MedEd https://t.co/g1xm9eg8b1 - view on twitter
Mashup Score:16
ScienceDirectFor patients with newly diagnosed multiple myeloma (MM) undergoing high dose chemotherapy-autologous stem cell transplant (HDT-ASCT), hematopoietic...
The addition of daratumumab to induction with VRd (Dara-VRd) did not lead to any clinically significant differences in stem cell yield and number of collection days, provided patient received pre-emptive GCSF and plerixafor #mmsm #bmtsm @hamzahashmi87 https://t.co/tbmvqx0f1q - view on twitter
Mashup Score:15
ScienceDirectChimeric antigen receptor (CAR) T cell (CAR-T) therapy represents a revolutionary treatment for patients with relapsed/refractory hematologic...
RT @CARTTherapy: Apoptosis of Hematopoietic Stem Cells Contributes to Bone Marrow Suppr... https://t.co/wiXDHWuLId #CART #bmtsm #immunoth… - view on twitter
Mashup Score:14
cibmtr.orgCIBMTR Working Committee Training and Leadership (CTL) Program - 1 month
Mashup Score:14
Opportunities for Early Career Investigators We are proud to announce a new CIBMTR Training and Leadership Program specifically for Early Career Investigators (ECI). As...
Nice to see this great opportunity for Early Career investigators in #bmtsm (ideally 3-7 years from fellowship) : @CIBMTR Working Committee Training and Leadership Program. Application https://t.co/TtwE4FcR8g @ASTCT #Tandem23 https://t.co/TtwE4FcR8g - view on twitter
Mashup Score:13
PubMedCase series: CYP Inhibition and low dose ibrutinib for steroid-refractory chronic graft-versus-host...
Low dose ibrutinib plus itraconazole create a new promising option in #GVHD #BMTsm Link to the article: https://t.co/12iMi2LzZz https://t.co/12iMi2LzZz - view on twitter
Mashup Score:12
American Society of HematologyKey Points. Axicabtagene ciloleucel induced long-term survival with no new safety signals in patients with refractory large B-cell lymphomaDurable responses...
RT @CARTTherapy: 5-Year Follow-Up Supports Curative Potential of Axi-cel in Refractory LBCL (ZUMA-1) https://t.co/gxuBuw7ZRr #CART #bmtsm… - view on twitter
5-Year Follow-Up Supports Curative Potential of Axi-cel in Refractory LBCL (ZUMA-1) https://t.co/gxuBuw7ZRr #CART #bmtsm #CARTcell #immunotherapy #tcellrx #ICAN #CRS #CARTcells #CellTherapy #Gene #Genetherapy @ASTCT @CARTTherapy @CART_Therapy @BloodJournal @BloodAdvances - view on twitter
We are proud to announce a new CIBMTR Training and Leadership Program specifically for Early Career Investigators...
Junior faculty apply for this great opportunity @CIBMTR Working Committee Training and Leadership (CTL) Program #bmtsm #CARTcells https://t.co/c10Z9xGB3q - view on twitter